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Abstract
Background: Free fatty acids released from adipose tissue affect the synthesis of apolipoprotein B-containing lipoproteins
and glucose metabolism in the liver. Whether there also exists a reciprocal metabolic arm affecting energy metabolism in
white adipose tissue is unknown.
Methods and Findings: We investigated the effects of apoB-containing lipoproteins on catecholamine-induced lipolysis in
adipocytes from subcutaneous fat cells of obese but otherwise healthy men, fat pads from mice with plasma lipoproteins
containing high or intermediate levels of apoB100 or no apoB100, primary cultured adipocytes, and 3T3-L1 cells. In
subcutaneous fat cells, the rate of lipolysis was inversely related to plasma apoB levels. In human primary adipocytes, LDL
inhibited lipolysis in a concentration-dependent fashion. In contrast, VLDL had no effect. Lipolysis was increased in fat pads
from mice lacking plasma apoB100, reduced in apoB100-only mice, and intermediate in wild-type mice. Mice lacking
apoB100 also had higher oxygen consumption and lipid oxidation. In 3T3-L1 cells, apoB100-containing lipoproteins
inhibited lipolysis in a dose-dependent fashion, but lipoproteins containing apoB48 had no effect. ApoB100-LDL mediated
inhibition of lipolysis was abolished in fat pads of mice deficient in the LDL receptor (Ldlr
2/2Apob
100/100).
Conclusions: Our results show that the binding of apoB100-LDL to adipocytes via the LDL receptor inhibits intracellular
noradrenaline-induced lipolysis in adipocytes. Thus, apoB100-LDL is a novel signaling molecule from the liver to peripheral
fat deposits that may be an important link between atherogenic dyslipidemias and facets of the metabolic syndrome.
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Introduction
Lipoproteins containing apolipoprotein (apo) B are synthesized
in the liver (apoB100-very low density lipoproteins (VLDL)) or the
intestine (apoB48-chylomicrons). These particles are released into
the circulation, where they undergo hydrolysis by lipoprotein
lipase, generating free fatty acids that are taken up by peripheral
organs such as the adipose tissue. The hydrolysis also generates
atherogenic remnants such as, apoB100-low density lipoprotein
(LDL), a major risk factor for atherosclerosis [1].
The intracellular lipolysis of adipocytes is believed to play a
central role in regulating whole-body energy homeostasis [2],
affecting both the release of free fatty acids to the circulation and
the extent of peripheral fat deposits. These effects provide a
metabolic link between peripheral fat deposits and the liver that
influence the hepatic synthesis and secretion of lipoproteins [2].
However, the existence and possible nature of a reciprocal signal
from the liver to the adipocytes have not been established.
The size and binding properties of apoB-containing lipoproteins
imply that they may have physiological functions other than the
passive transport of lipids to adipocytes. Indeed, individuals with
conditions characterized by high levels of apoB-containing
lipoproteins have reduced levels of catecholamine-induced lipolysis
in their adipocytes [3,4].
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3771We hypothesized that apoB-containing lipoproteins affect
adipocyte lipolysis, serving as a signal from the liver to peripheral
fat deposits. To test this hypothesis, we investigated lipolysis in
subcutaneous fat cells from obese but otherwise healthy men in
relation to their levels of apoB-containing lipoproteins. We then
examined noradrenaline-induced lipolysis in genetically modified
mouse models with plasma containing high or intermediate levels
or no apoB100 or apoB48, and human primary cultured
adipocytes and 3T3—L1 cells incubated with different types and
concentrations of human and mouse apoB-containing lipopro-
teins. Taken together, our findings show that apoB100-LDL act as
a metabolic signal causing inhibition of lipolysis in adipocytes.
Results
Lipolysis in healthy volunteers and human primary
adipocytes
In accordance with previous observations [3,4], the rate of
noradrenaline-induced lipolysis in subcutaneous fat cells from
obese but otherwise healthy men correlated strongly and inversely
with apoB plasma levels (r=20.5, Fig. 1A) but was not related to
apoA1 or body mass index (both r=0.1; not shown), suggesting
that apoB100-containing lipoproteins suppresses adipocyte lipol-
ysis. The inverse correlation was also found to be independent of
age and markers of the metabolic syndrome. This was investigated
by multiple regression analysis using the following markers for
metabolic syndrome and noradrenaline-induced lipolysis together
as regressors versus apoB100 as a dependent factor, age;
r=20.27, p=0.018; waist: r=20.35, p=0.005; fasting plasma
insulin: r=20.36, p=0.002; fasting plasma HDL cholesterol:
r=20.36, p=0.002; fasting plasma triglycerides: r=20.32;
p=0.003; systolic blood pressure: r=20.26, p=0.023; diastolic
blood pressure: r=20.24, p=0.032.
To determine the cause-effect relationship, we differentiated
human preadipocytes into adipocytes and exposed them to equal
numbers of human VLDL or LDL particles (i.e., equal
concentrations of apoB100). Spontaneous (basal) lipolysis was
unaffected (Fig. 1B); however, noradrenaline-induced lipolysis was
markedly inhibited by LDL, but not by VLDL (Fig. 1C), in a
concentration-dependent fashion (Fig. 1D) after incubation for
48 hours (Fig. 1E).
Reconstitution of the cholesterol esters content of the native
LDL particles with triglycerides or cholesterol ester (experimental
control) did not alter the inhibition of noradrenaline-induced
lipolysis (Fig. 1F).
In our previous studies of lipolysis in hyper-apoB100 conditions,
noradrenaline-induced lipolysis was attenuated at the level of the
protein kinase A (PKA)–hormone sensitive lipase (HSL) complex
[3,4]. RT-PCR analyses of human adipocytes incubated with LDL
revealed that the mRNA levels of the regulatory 1a subunit of the
PKA were decreased (Reg1a;p ,0.01), whereas that of the
regulatory 2b subunit were increased (Reg 2b;p ,0.05). LDL
incubation did not influence the mRNA levels of HSL or adipose
triglyceride lipase (ATGL) [5]. In the fatty acid oxidation pathway,
the mRNA levels of carnitine palmitoyltransferase 1 (CPT1) and
peroxisome proliferator activated receptor alpha (PPARa) were
increased, p,0.05 and p,0.01, respectively (Fig. 1G).
Lipolysis in Fat Pads in Relation to Plasma apoB in Mouse
To assess the role of different types of apoB-containing
lipoproteins in vivo, we investigated fat pad lipolysis in mice that
conditionally lack microsomal triglyceride transfer protein in the
liver (Mttp
D/D) [6] (and therefore have no apoB100-containing
lipoproteins in plasma), in wild-type mice with both apoB100 and
apoB48, and in mice expressing only apoB100 [7] (Fig. 2A). These
groups exhibited no differences in fat cell size (Fig. 2B), body
weight (Table 1), or basal lipolysis (Fig. 2C). However, lipolysis
induced by noradrenaline (at the maximal effective concentration)
or 8-bromo cyclic AMP was increased in mice lacking apoB100,
reduced in apoB100-only mice, and intermediate in wild-type
mice (Fig. 2C). Dose-response experiments showed similar
hormone sensitivities in all three groups (not shown).
Of note, mice lacking apoB100 and apoB100-only mice had
lower plasma triglyceride and cholesterol levels than wild-type
mice (Table 1), implying that plasma concentrations of cholesterol
and triglycerides per se did not affect lipolysis in adipocytes. The
increased lipolysis in mice lacking apoB100 did not lead to a leaner
phenotype or to smaller fat cells, suggesting adaptive or parallel
changes in whole-body energy metabolism. Indeed, oxygen
consumption was increased (VO2, Fig. 2D) in these mice—but
only at high temperatures, when lipid oxidation was concomitantly
increased, as evidenced by a lower respiratory quotient (RQ,
Fig. 2D). However, food intake was almost identical in both groups
(Fig. S1, Supplementary online material). These results suggest
that mice lacking apoB100 decrease their circulating lipids rather
than body fat as a result of the increase in catecholamine-induced
lipolysis by enhancing energy expenditure and fat oxidation.
Types of apoB and lipolysis in mouse adipocytes
Our mouse in vivo studies implied that apoB100-containing but
not apoB48-containing lipoproteins affect noradrenaline-induced
lipolysis in adipocytes. To explore this possibility further, we
exposed 3T3-L1 adipocytes to equal amounts of mouse lipopro-
teins containing either apoB100 or apoB48. ApoB100 lipoproteins
inhibited noradrenaline-induced but not basal lipolysis (Fig. 3A) in
dose-dependent fashion (Fig. 3B). ApoB48 lipoproteins did not
affect lipolysis (Fig. 3A). Thus, lipoproteins containing apoB100,
but not those containing apoB48, are responsible for the
interaction with adipocytes, leading to reduced lipolysis within
these cells.
The role of the LDL receptor on adipocytes
Since the LDL receptor (LDLR) is expressed on adipocytes [8],
we investigated its role in the interaction between apoB100
lipoproteins and adipocytes by analyzing apoB100-only mice that
expressed the LDLR (Ldlr
+/+Apob
100/100) or were LDLR-deficient
(Ldlr
2/2Apob
100/100) [9]. Apart from their plasma cholesterol
levels, the two groups were phenotypically similar (values not
shown). LDLR deficiency did not affect fat cell size (Fig. 3C) but
decreased basal lipolysis slightly (Fig. 3D). Importantly, however,
noradrenaline-induced glycerol release was almost threefold
higher in Ldlr
2/2Apob
100/100 mice (Fig. 3D), suggesting that
binding of apoB100-LDL to the LDLR is necessary to mediate the
inhibition of lipolysis in adipocytes.
Discussion
ApoB100 is the main cholesterol transporter in the circulation
and has a central role in atherogenesis. In this study, we show that
plasma apoB100-containing lipoproteins interact directly with
adipocytes, resulting in lower levels of catecholamine-induced
lipolysis. VLDL and apoB48-containing lipoproteins had no effect
on lipolysis, indicating that the interaction with adipocytes requires
the LDLR. We also provide evidence that apoB100-LDL
modulates lipid mobilization and energy expenditure. These
findings reveal a novel role for apoB100-LDL as a signaling
molecule between the liver and adipose tissues that may provide
ApoB100-LDL and Lipolysis
PLoS ONE | www.plosone.org 2 November 2008 | Volume 3 | Issue 11 | e3771Figure 1. Effects of apoB100, VLDL, and LDL on lipolysis in human fat cells. (A) Linear regression plot of fat cell lipolysis (glycerol release)
and plasma apoB100 levels in 48 overweight but healthy men. The linear regression r-value=20.5, p,0.001. (B) Basal (n=9; p=0.94; DF=2,24; F-
value=0.065) and (C) noradrenaline-stimulated (noradrenaline/basal) (n=9; p,0.05; DF=2,24; F-value=3.6) lipolysis in human differentiated pre-
adipocytes incubated with equal concentrations (40 mg apoB100/ml medium) of human VLDL or LDL or with vehicle alone for 48 hours. (D) Inhibition
of lipolysis in human differentiated pre-adipocytes incubated without or with human LDL at five concentrations (20, 30, 40, 60, 80 mg apoB100/ml
medium) for 48 hours (n=3 for each concentration; p=0.001; DF=2,5,10; F-value=10.4) and (E) with different incubation times (8, 24 and 48 hours)
with 40 mg apoB100/ml medium (n=5 for each time point; DF=2,12) p=0.61; F-value=0.48 for vehicle and p=0.007; F-value=7.6 for apoB100
incubation. (F) Noradrenaline-stimulated (noradrenaline/basal) lipolysis in human differentiated pre-adipocytes incubated with vehicle alone, native
LDL and two forms of reconstituted LDL (40 mg apoB100/ml medium) for 48 hours (n=29–34 in each group). ‘‘Trilinoleate’’ indicates reconstituted
LDL in which cholesterol esters had been replaced with Trilinoleate. ‘‘Chol. linoleate’’ indicates reconstituted LDL in which cholesterol esters had been
ApoB100-LDL and Lipolysis
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metabolic syndrome.
A role of apoB100-LDL as a liver–adipose signal is consistent
with the notion that the liver is a major regulator of whole-body
energy homeostasis and that white adipose tissue is an important
energy reserve [10]. Indeed, fatty acids function as signaling
molecules in the reverse direction, from the adipose tissue to the
liver. During sympathetic activation, white adipose tissue releases
fatty acids into the circulation at higher rates, at least in part
through catecholamine-mediated activation of protein kinase A.
This stimulates lipid oxidation and energy expenditure. The liver
responds by increasing VLDL synthesis (Fig. 4A). The physiolog-
ical significance of the observed correlation between plasma
apoB100 levels and fat cell lipolysis (Fig. 1A) needs, however, to be
Figure 2. Effects of apoB100 in mice. Plasma and gonadal fat pads were isolated after an overnight fast from 10-week-old wild-type mice (B100/
B48) and mice lacking apoB100 (B48) or expressing only apoB100 (B100). (A) Western blots of plasma performed with rabbit anti-mouse apoB
antibodies. (B) Gonadal fat pad cell volume (n$12 mice per group (B100/B48;B48; B100); p=0.99; DF=2,35; F-value=0.015). (C) Basal (p=0.13;
DF=2,39; F-value=2.4), noradrenaline-stimulated (p=0.019; DF=2,36; F-value=3.8), and 8-bromo cyclic AMP–stimulated lipolysis (p=0.02;
DF=2,38; F-value=3.8) (n$12 mice per group). (D) Resting oxygen consumption (VO2) and respiratory quotient (RQ) in mice kept at different
environmental temperatures (n=7–8 mice mice per group; DF=1,13) p=0.01; F-value=3.3 for VO2 and p=0.015; F-value=3.1 for RQ). Error bars in
(B–D) indicate SD. p-values were determined by ANOVA.
doi:10.1371/journal.pone.0003771.g002
replaced with cholesteryl linoleate. (G) mRNA expression (n=4–8) in human differentiated pre-adipocytes incubated with human LDL (40 mg
apoB100/ml medium) presented as % of control cells (not exposed to LDL). Error bars in (B,C,G) indicate SD and in (D,E,F) indicate SE. p-values for (B,
C, D, E) were determined by ANOVA and for (F,G) un paired t-test. *p,0.05, **p,0.01, ***p,0.001 indicate Fisher’s Post-hoc test.
doi:10.1371/journal.pone.0003771.g001
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be a consequence of one or several differential expressed genes
with independent effects on both apoB100 plasma levels (either by
affecting synthesis in the liver or clearance in the periphery) and
lipolysis in fat cells.
Our findings suggest that decreased LDL concentrations in the
microcirculation of adipose tissue cause a reciprocal activation of
lipolysis in white adipose tissue when apoB100-LDL levels are
decreased. In FCHL and metabolic syndrome, which are
characterized by very high levels of apoB100 [11], a liver–adipose
tissue route could potentially be involved. We speculate that, when
catecholamine-induced adipocyte lipolysis decreases [3,4], adipo-
cyte lipid synthesis is lowered to compensate for the reduced
lipolysis. In support of this notion, lipid synthesis stimulation by
acylation-stimulating protein is decreased in FCHL [12,13].
Patients with FCHL have increased apoB100 levels and decreasing
catecholamine-induced lipolysis but the fat cell size remains
normal, suggesting a link between low lipolysis and low lipid
synthesis in fat cells. Reduced turnover of lipids in fat cells [3] may
lead to decreased adipocyte fatty acid trapping and elevated levels
of circulating fatty acids, which in turn exacerbate the dyslipide-
mia [14,15] (Fig. 4B).
There are numerous possibilities for how the interaction
between apoB100-LDL and adipocyte LDLR may influence
catecholamine signaling to the adipose tissue. The LDLR itself
may mediate second signaling by mediating the uptake and
degradation of LDL particles, which in turn may release molecules
with signaling properties [16,17]. We tested whether the
cholesterol ester content of the apoB100-LDL particles may alter
their inhibitory effects on catecholamine-induced lipolysis. How-
ever, reconstituting cholesterol esters of the apoB100-LDL
particles with triglycerides had no effect (Fig. 1F). Despite this,
we found that apoB100-LDL signaling through the LDLR altered
gene expression of several genes whereof two in the PKA complex
(Fig. 1G). The gene expression observations are consistent with the
Table 1. Basic Characteristics of the Study Mice.
Genotype
ApoB100 ApoB100/48 ApoB48
(Apob
100/100)( wild-type)( Mttp
D/D)
Characteristics (n=5) (n=5) (n=5)
Age (weeks) 10 10 10
Body weight (g) 27.160.57 29.462.6 29.762.0
Liver weight (g) 1.560.1
* 1.360.05 1.560.09
{
Plasma triglycerides (mg/dl) 33.1610.6* 67.8629.6 17.967.0
*
Plasma cholesterol (mg/dl) 19.1614.6
{ 99.1616.5 38.5613.7
{
Plasma glucose (mg/dl) 361642 373620 360631
Values are mean6SD.
*p,0.05,
{p,0.005 vs. apoB100/48 mice. Plasma were
isolated after an overnight fast.
doi:10.1371/journal.pone.0003771.t001
Figure 3. Effects of mouse apoB100 on 3T3-L1 cells and effects of Ldlr in the study mice. (A) Basal and noradrenaline-stimulated lipolysis
in 3T3-L1 cells incubated with equal numbers of mouse lipoproteins containing only apoB100 (40 mg/ml medium, n=10) or apoB48 (20 mg/ml
medium, n=4) or with vehicle alone (n=7) for 48 hours; DF=2,18 (p=0.79; F-value=0.24 for basal and p,0.001; F-value=10.4 for noradrenaline-
stimulated lipolysis). (B) Percent inhibition of lipolysis mediated by incubation of 3T3-L1 cells with mouse lipoproteins containing apoB100 at high
(80 mg apoB/ml medium) and low (40 mg apoB/ml medium) concentrations or with vehicle alone (Control) (n=9 for each concentration; p=0.013;
DF=2,24; F-value=5.6) for 48 hours. (C) Fat cell volume in gonadal fat pads isolated from Ldlr
2/2Apob
100/100 mice (Ldlr
2/2, n=13) and Ldlr
+/
+Apob
100/100 mice (Ldlr
+/+, n=17) mice (p=0.23). (D) Basal (p,0.05) and noradrenaline-stimulated (p,0.01) lipolysis in the mice described in (C). Error
bars indicate SD. p-values were determined by ANOVA in (A–B) and unpaired t-test in (C–D), *p,0.05, **p,0.01 (t-test).
doi:10.1371/journal.pone.0003771.g003
ApoB100-LDL and Lipolysis
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and Reg2b in Reg1a-null mutant mice and the findings of lipolysis
studies with selective PKA blockers in mouse fat cells [18–20] are
in agreement with a decrease in catecholamine-induced lipolysis.
Furthermore, knockout of Reg2b results in a compensatory
increase in Reg1a [18,19]. The induction of apoB100-LDL of
genes regulating fatty acid oxidation (CPT1, PPARa) are, in our
view, in agreement with the measurements of metabolic rates
(VO2 and RQ, Fig. 2D). A decrease in catecholamine-induced
lipolysis seems to be coupled with an increase in fatty acid
oxidation, thus the two phenomena appear to compensate each
other which also is consistent with the absence of changes in fat
cell volumes (Fig. 2B). However, the exact mechanism for how the
LDLR/apoB100-LDL complex mediates changes to gene expres-
sion and inhibitory effect on lipolysis remains a topic for future
studies.
In conclusion, we have shown that apoB100-LDL mediates the
inhibition of catecholamine-induced lipolysis in adipocytes
through the LDLR. Our findings suggest a novel link between
dyslipidemias and metabolic disorders such as FCHL and the
metabolic syndrome. They also suggest that the beneficial actions
of cholesterol-lowering agents such as statins may involve effects
on the rate of lipolysis in adipocytes.
Materials and Methods
Subjects
The study subjects were 48 overweight but otherwise healthy
Scandinavian men (body mass index, 25–53 kg/m
2), aged 23–
72 years, who were free from regular medication. In the
morning after an overnight fast, a venous blood sample was
obtained for analysis of serum apoB100 and apoA1 concentra-
tions, and a subcutaneous fat biopsy (1–3 g) was obtained from
the abdominal region by needle aspiration under local
anesthesia as described [21]. For experiments in primary
cultures of human pre-adipocytes, subcutaneous adipose tissue
was obtained during cosmetic liposuction under general
anesthesia from healthy subjects who were not selected on
the basis of age, sex, or degree of obesity. The study was
approved by the hospital’s ethics committee. The study was
explained in detail to each participant and written informed
consent was obtained.
Mouse models
In the Mttp
flox/floxMx1-Cre
+/2 mice used for the study, the gene
for microsomal triglyceride transfer protein is floxed (Mttp
flox/flox)
and can be recombined in the liver upon induction of Cre-
recombinase (Mx1-Cre
+/2) with polyinosinic-polycytidylic ribonu-
cleic acid (1 mg/ml; Sigma). This recombination results in the
termination of hepatic VLDL synthesis and depletion of plasma
apoB100, as described [6]. Two weeks before sacrifice, Mttp was
recombined (Mttp
D/D), which interrupts hepatic synthesis of
apoB100-containing lipoproteins, leaving only apoB48-containing
lipoproteins in plasma (Fig. 2A). Littermate wild-type mice
(Mttp
flox/flox), injected with phosphate-buffered saline, had approx-
imately equal concentrations of plasma apoB100 and apoB48, as
shown by western blot analysis, while Apob
100/100 mice [7] only
had apoB100 in plasma (Fig. 2A). Ldlr
2/2Apob
100/100 and Ldlr
+/
+Apob
100/100 mice were generated by crossing Ldlr
2/2 mice [9]
with Apob
100/100 mice. The study mice had been backcrossed at
least six times (.95% C57BL/6, ,5% 129/SvJae), were housed
in a pathogen-free barrier facility (12 h light/12 h dark cycle), and
were fed rodent chow containing 4% fat. Genotypes were
determined by polymerase chain reaction using genomic DNA
from tail biopsies. Mice were sacrificed at 10 weeks of age.
Gonadal and renal fat pads were immediately removed and put
into tubes containing 37uC phosphate-buffered saline for following
analyses.
Figure 4. Model for cross-talk between the liver and adipose-tissue. In the normal state there is a balance between production of hepatic
apoB100 containing lipoproteins and release of free fatty acid (FFA) from the adipose tissue. In FCHL patients, who have lower noradrenaline-induced
lipolysis and increased levels of plasma lipoproteins containing aoB100, lowered lipid synthesis and decreased adipocyte fatty acid trapping lead to
elevated levels of FFA in the circulation. Increased levels of circulating FFA activate apoB100 synthesis leading to elevated plasma apoB100
containing lipoprotein levels. In this fashion an imbalance between liver-adipose tissue is created and a ‘‘vicious circle’’ evolves. HSL indicates
hormone sensitive lipase.
doi:10.1371/journal.pone.0003771.g004
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Mouse plasma samples (2 ml) were fractionated by SDS-PAGE
using 4% gels. The apoB proteins were detected with rabbit
antiserum against mouse apoB (Biosite, Taby, Sweden). The
binding of primary antibodies was assessed with horseradish
peroxidase–labeled donkey anti-rabbit antibodies and ECL
western blotting reagents (Amersham Biosciences, GE Healthcare
Biosciences, Little Chalfont, Buckinghamshire, England). Plasma
cholesterol and triglyceride concentrations were determined with
colorimetric assays (Infinity cholesterol/triglyceride kits; Thermo
Electron, Melbourne, Australia). Plasma glucose levels were
measured with Precision Xtra (MediScience, Cherry Hill, NJ).
Eight mice lacking apoB100 (Mttp
D/D) and seven wild-type
(Mttp
flox/flox) mice were investigated in metabolic cages, and food
intake was recorded. Energy expenditure and respiratory quotient
were determined at week 10 as described [22]. In brief, after an
acclimatization period, oxygen consumption and carbon dioxide
production were measured at 15–32.5uC. Experiments conducted
at temperatures of 15–27.5uC lasted for up to 5 hours; those
conducted at temperatures above 27.5uC lasted for 2.5 hours (to
avoid stress caused by the heat). Oxygen consumption (ml/min/
kg
0.75) and the respiratory quotient were calculated with a
calorimetry calculation program (written in DasyLab; Somedic,
Horby, Sweden).
RNA Isolation and Real-Time PCR
Human subcutaneous fat that had been stored in Trizol reagent
at 280uC were homogenized (FastPrep, Qbiogene; Irvine, CA) in
fresh Trizol. Total RNA was prepared with RNeasy mini kits
(Qiagen, Valencia, CA) using a DNAse I treatment step according
to the manufacturer’s protocol. RNA quality was assessed with a
Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA).
Total RNA (0.3–0.5 mg) was reverse transcribed with Superscript
II as recommended by the manufacturer (Invitrogen). After
dilution to 65 ml, cDNA (3 ml) was amplified by real-time PCR
with 16TaqMan universal PCR master mix (Applied Biosystems,
Foster City, CA). Assay-on-Demand kits containing corresponding
primers and probes were from Applied Biosystems. The mRNA
levels were normalized to acidic ribosomal phosphoprotein P0
(RPLP0).
Lipoprotein isolation
Human VLDL and LDL in 60 ml of blood from a normolipi-
demic donor were isolated by density-gradient ultracentrifugation,
as described [23]. In brief, after a 16-hour spin in a Beckman
SW40 rotor at 40,000 rpm at 15uC, the top 0.5 ml layer was
aspirated (VLDL). The tubes were then sliced 42 mm from the top
to harvest the LDL fraction. The LDL and VLDL fractions were
each passed through a PD-10 desalting column (Amersham
Bioscience). Mouse lipoproteins containing apoB48 or apoB100
were isolated from plasma pooled from 8 Mttp
D/D mice and 8
Apob
100/100 mice, respectively. The pooled plasma was mixed with
1.42 g/ml NaBr to a final density of 1.10 g/ml and ultracentri-
fuged at 40,000 rpm in a Beckman SW40 rotor for .80 hours at
10uC. The top 0.5 ml of the tube containing LDL and less dense
lipoproteins was collected. ApoB concentrations in the lipoprotein
fractions were assessed from total protein concentrations. The
LDL fractions used in the current experiments contained
5.461.9 mmol/L cholesterol, 0.5860.12 mmol/l triglycerides
and 483662 mg/l apoB100. We have run aliquots of these
fractions on SDS-acrylamide gels showing a robust apoB100 band
and no other degradation products or other proteins (data not
shown).
Preparation of reconstituted low density lipoprotein
Reconstituted LDL was prepared as described by [24]. In brief,
LDL was dialyzed at 4uC against 0.3 mM EDTA, pH 7.0.
Aliquots of 1.9 mg LDL were transferred to glass tubes containing
25 mg of potato starch and frozen in liquid nitrogen. The samples
were lyophilized and the endogenous lipids were extracted from
the lyophilized LDL with heptane. After removing the last heptane
supernatant, 200 ml heptane containing 6 mg of glyceryl trilinole-
ate or cholesteryl linoleate (Sigma-Aldrich) were added. The
mixture was incubated for 1 hour at 4uC followed by evaporation
of the heptane under a gentle stream of nitrogen until the samples
were completely dry. One ml of PBS, pH 7.4, was then added to
dissolve the reconstituted LDL and left overnight at 4uC. The
solubilized reconstituted LDL was separated from the bulk of the
starch and from excess lipids by centrifugation at 2000 rpm for
10 min, 4uC. The supernatant was further centrifuged at 9100 g
for 10 min, 4uC and finally filtered through a 0.22 mm Millipore
filter.
Adipose tissue and cell cultures
Human subcutaneous adipose tissue and mouse fat pads were
cut into fragments, incubated with collagenase (0.5 g/ml; Sigma,
St. Louis, MO) in Krebs Ringer phosphate buffer (pH 7.4)
supplemented with 40 g/l dialyzed bovine serum albumin
(fraction V; Sigma) for 1 hour at 37uC, and filtered through a
nylon mesh. The supernatant, containing mature adipocytes, was
used as described below.
Pre-adipocytes were isolated and differentiated as described
[25]. The cell pellet obtained from human subcutaneous adipose
tissue was resuspended in 10 ml of erythrocyte lysis buffer
(0.154 M NH4Cl, 5.7 mM K2HPO4, and 0.1 mM EDTA,
pH 7.3) and centrifuged. The pellet was resuspended in 10 ml of
DMEM/F12 medium (Invitrogen) and filtered through a nylon
filter. After an additional centrifugation, the cells were resus-
pended in DMEM/F12 supplemented with 10% fetal calf serum
and penicillin/streptomycin (100 mg/l), seeded into 12-well plates
(50,000 cells/cm
2), and kept at 37uC in 5.3 kPa CO2 for 18–
20 hours. Cells were then washed with DMEM/F12 and cultured
in chemically defined serum-free medium. Rosiglitazone (kindly
provided by SmithKline Beecham Pharmaceuticals) was added to
a final concentration of 10 mmol/l (days 1–6) to induce
differentiation. Cells were maintained in the medium at 37uC
and 5.3 kPa CO2 for a total of 10 days and incubated with fresh
lipoproteins for 8, 24, or 48 hours. Only cultures with a
differentiation density $70% and ,5% contaminating endothelial
cells were used. Differentiation was determined by quantifying
glycerol-3-phosphate dehydrogenase activity as described [25].
Standard procedures were used to grow and differentiate 3T3-L1
cells. Lipolysis experiments with differentiated 3T3-L1 cells or
human pre-adipocytes were conducted as described [26]. In brief,
pre-adipocytes were incubated in medium with or without fresh
mouse or human lipoproteins for 48 hours. The medium was
removed, and the cells were washed and incubated for 3 hours at
37uC in DMEM/F12 medium supplemented with bovine serum
albumin (20 g/l) with and without noradrenaline (10
24 mol/l). In
methodological experiments, 10
24 mol/l of noradrenaline always
produced the maximal lipolytic effect. Aliquots were collected and
kept at 220uC for measurement of glycerol concentration (an index
oflipolysis).To controlforinterexperimentaldifferencesinadipocyte
differentiation, glycerol release was normalized to the glycerol-3-
phosphate dehydrogenase activity and protein content of each
sample.
Mature collagenase-isolated fat cells were used for lipolysis
experiments as described [3,4]. The same lipolysis protocol was
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measured in one of the two gonadal fat pads from each mouse. In
preliminary experiments, similar results were obtained with gonadal
fat pads and equal amounts of renal adipose tissue. Fat-cell size and
number were measured (see below) [27]. In lipolysis experiments,
diluted cell suspensions (2%, vol/vol) were incubated in albumin-
containing buffer, pH 7.4, containing glucose (1 g/l) and ascorbic
acid (0.1 g/l) for 2 hours at 37uC with air as the gas phase. Glycerol
release into the medium was determined by bioluminescence as
described [28] and expressed as mol ? 10
26 ? 2h
21 ? cells ? 10
27.
Adipocyteswere incubated inthe absence orpresenceof10
26 mol/l
noradrenaline and 10
23 mol/l 8-bromo cyclic AMP (a phosphodi-
esterase-insensitive cyclic AMP analogue). In the clinical experi-
ments isolated human fat cells were also incubated with isoprenaline
10
26 mol/l (nonselective beta adrenergic agonist) and forskolin
10
24 mol/l (activator of adenylyl cyclase). These concentrations of
lipolytic agents always yielded maximal stimulation in mature
adipocytes in control experiments. When several hormone concen-
trations were used, the concentration-response curves were analyzed
for half-maximum effective concentration.
Measurement of fat cell size and volume
Meanfatcellsizeand volumeweredeterminedonisolatedfatcells
as follows: Fat cell diameter was measured in direct microscopy and
averaging the diameter of 100 cells in each individual or mouse. The
mean fat cellvolume and sizewerecalculated byformulasdeveloped
byHirschandGallian [29].Coefficientof variation forthe methodis
2–3%.The meanvalues are essentially thesameas thosedetermined
from fat cell sizing of intact pieces of human adipose tissue [30].
Total number of fat cells inthe body was calculated asthe amount of
body fat divided by the mean fat cell weight. It is well known that
mean fat cell volume and weight differs between various adipose
regions in man. However, the differences are small and only
introduce a marginal error when just one depot is used for the
calculation of total fat cell number as discussed [31].
Statistical analyses
Values were compared with unpaired t tests, simple and
multiple regression analyses, or analysis of variance (ANOVA)
followed by Fisher’s post-hoc test. Data with a skewed distribution
were log normalized before statistical analyses.
Supporting Information
Figure S1 Food intake in B100/48 (n=7) and B48 (n=8) mice.
Error bars indicate SD.
Found at: doi:10.1371/journal.pone.0003771.s001 (18.20 MB
TIF)
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